Expression and signification of transferrin receptor 1 in head-neck carcinoma_West China Medical Journal

Authors：

NI Xiaowei , JIANG Ying ,  TANG Yuedi

Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

TANG Yuedi, Email: tangyd@hotmail.com

Keywords：

Transferrin receptor 1; Carcinoma; Western blot

DOI：

10.7507/1002-0179.201703181

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect the expression of transferrin receptor 1 (TfR1) in laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma, exploring the relationship between the expression of the four cancers and their occurrence and progression. Methods A total of 24 specimens of head-neck carcinoma were collected in surgery from April 2015 to March 2017, including 8 cases of laryngeal carcinoma, 8 cases of thyroid carcinoma, 4 cases of maxillary sinus carcinoma, and 4 cases of parotid carcinoma. Fluorescence quantitative polymerase chain reaction technique for TfR1 mRNA and western blot for TfR1 protein was performed in those tumor tissues and their adjacent normal tissues. Results The relative expression level of TfR1 mRNA in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma was 0.078±0.002, 0.065±0.044, 0.076±0.014, 0.067±0.004, respectively; while the relative expression level of TfR1 mRNA in the adjacent normal tissues of the four cancers was 0.021±0.012, 0.011±0.007, 0.017±0.013, 0.028±0.007, respectively. The relative expression level of TfR1 protein in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma was 0.668±0.206, 0.640±0.066, 0.452±0.095, 0.925±0.221, respectively; while the relative expression level of TfR1 protein in the adjacent normal tissues of the four cancers was 0.359±0.113, 0.424±0.096, 0.280±0.093, 0.519±0.037, respectively. The expression levels of TfR1 mRNA and TfR1 protein in the tumor tissues of the four cancers were all higher than those in their adjacent normal tissues (P<0.05). Conclusions The expression levels of TfR1 mRNA and TfR1 protein in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma and parotid carcinoma are up-regulated. TfR1 may be involved in the occurrence and progression of the four cancers, and it may be responsible for tumor proliferation by providing necessary raw materials for the proliferation of tumor cells.

Citation： NI Xiaowei, JIANG Ying, TANG Yuedi. Expression and signification of transferrin receptor 1 in head-neck carcinoma. West China Medical Journal, 2017, 32(11): 1726-1729. doi: 10.7507/1002-0179.201703181 Copy

1.	Siegel R, Jemal A, Ma Jiemin, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
2.	邓太海, 陈舒华. 转铁蛋白受体与肿瘤疾病的关系. 海南医学, 2011, 22(5): 137-140.
3.	陈玥琦. 转铁蛋白受体与肿瘤疾病的关系. 实用肿瘤学杂志, 2015, 29(1): 65-68.
4.	张洪明. 转铁蛋白受体的结构、表达及功能. 实用临床医药杂志, 2008, 12(5): 114-117.
5.	Leplletier Y, Camara-Clayette V, Jin H, et al. Prevemion of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res, 2007, 67(3): 1145-1154.
6.	Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 2006, 121(2): 144-158.
7.	Giannetti AM, Snow PM, Zak O, et al. Mechanism for multiple ligand recognition by the human transferring receptor. PLoS Biol, 2003, 1(3): E51.
8.	陈舒华, 周少雄, 张继平, 等. 鼻咽癌高癌家系癌患者不同体质证型的蛋白质组学研究. 中国中西医结合耳鼻咽喉科杂志, 2013, 21(1): 5-9.
9.	Panieri E. Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol, 2012, 26(2): 283-290.
10.	原永明, 周雪颖, 韩倩, 等. 肝癌患者血清铁含量检测的临床意义. 检验医学, 2013, 28(6): 534-535.
11.	Theler JM. Bone tissue substitutes and replacements. Curr Opin Otolaryngol Head Neck Surg, 2011, 19(4): 317-321.
12.	刘双林, 王志华, 胡志全, 等. 抗人转铁蛋白受体单克隆抗体增强姜黄素对雄激素非依赖性前列腺癌的抑制效应. 华中科技大学学报: 医学版, 2012, 41(3): 284-287, 295.
13.	张莉, 徐维平, 陆杨, 等. 转铁蛋白-转铁蛋白受体在肿瘤主动靶向治疗中的应用. 中国药业, 2012, 5(21): 1-3.
14.	Zhang MX, Gurnerov DR, Kaltashov IA. Indirect detection of protein-metal binding: interaction of serum transferrin with In³⁺ and Bi³⁺. J Am Soc Mass Spectrom, 2004, 15(11): 1658-1664.
15.	王丛珠, 王登平, 郑佐娅. 转铁蛋白介导作用的应用进展. 放射免疫学杂志, 2003, 16(5): 304-306.
16.	汪溪, 李建业, 夏春咸. 双氢青蒿素抗肿瘤作用研究进展. 海南医学, 2010, 21(13): 119-121.
17.	Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med, 2004, 37(7): 998-1009.
18.	Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett, 2002, 179(2): 151-156.

1. Siegel R, Jemal A, Ma Jiemin, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
2. 邓太海, 陈舒华. 转铁蛋白受体与肿瘤疾病的关系. 海南医学, 2011, 22(5): 137-140.
3. 陈玥琦. 转铁蛋白受体与肿瘤疾病的关系. 实用肿瘤学杂志, 2015, 29(1): 65-68.
4. 张洪明. 转铁蛋白受体的结构、表达及功能. 实用临床医药杂志, 2008, 12(5): 114-117.
5. Leplletier Y, Camara-Clayette V, Jin H, et al. Prevemion of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res, 2007, 67(3): 1145-1154.
6. Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 2006, 121(2): 144-158.
7. Giannetti AM, Snow PM, Zak O, et al. Mechanism for multiple ligand recognition by the human transferring receptor. PLoS Biol, 2003, 1(3): E51.
8. 陈舒华, 周少雄, 张继平, 等. 鼻咽癌高癌家系癌患者不同体质证型的蛋白质组学研究. 中国中西医结合耳鼻咽喉科杂志, 2013, 21(1): 5-9.
9. Panieri E. Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol, 2012, 26(2): 283-290.
10. 原永明, 周雪颖, 韩倩, 等. 肝癌患者血清铁含量检测的临床意义. 检验医学, 2013, 28(6): 534-535.
11. Theler JM. Bone tissue substitutes and replacements. Curr Opin Otolaryngol Head Neck Surg, 2011, 19(4): 317-321.
12. 刘双林, 王志华, 胡志全, 等. 抗人转铁蛋白受体单克隆抗体增强姜黄素对雄激素非依赖性前列腺癌的抑制效应. 华中科技大学学报: 医学版, 2012, 41(3): 284-287, 295.
13. 张莉, 徐维平, 陆杨, 等. 转铁蛋白-转铁蛋白受体在肿瘤主动靶向治疗中的应用. 中国药业, 2012, 5(21): 1-3.
14. Zhang MX, Gurnerov DR, Kaltashov IA. Indirect detection of protein-metal binding: interaction of serum transferrin with In³⁺ and Bi³⁺. J Am Soc Mass Spectrom, 2004, 15(11): 1658-1664.
15. 王丛珠, 王登平, 郑佐娅. 转铁蛋白介导作用的应用进展. 放射免疫学杂志, 2003, 16(5): 304-306.
16. 汪溪, 李建业, 夏春咸. 双氢青蒿素抗肿瘤作用研究进展. 海南医学, 2010, 21(13): 119-121.
17. Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med, 2004, 37(7): 998-1009.
18. Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett, 2002, 179(2): 151-156.

West China Medical Journal

Expression and signification of transferrin receptor 1 in head-neck carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content